-
MDT Diagnosis and Treatment of Thoracic and Pulmonary Respiratory Diseases_Chengdu Traditional Chinese Medicine Asthma Hospital, Chengdu Traditional Chinese Medicine Pulmonary Hospital
Time of Update: 2023-01-05
MDT Diagnosis and Treatment of Thoracic and Pulmonary Respiratory Diseases_Chengdu Traditional Chinese Medicine Asthma Hospital, Chengdu Traditional Chinese Medicine Pulmonary HospitalAuthor: Meilin is located at: Health Encyclopedia The MDT model is multidisciplinary joint diagnosisIt was first proposed by Mayo Jane in the United States in the last centuryAfter the 90s, it developed rapidly and continued to improve.
-
Hot flashes are not only uncomfortable, they can also cause damage to the heart
Time of Update: 2022-10-20
A growing body of research calls into question this long-standing clinical wisdom and highlights that frequent or severe hot flashes may predict an increased risk of cardiovascular disease in women in middle age and beyond," Dr. Thurston said.
-
What about nocturnal enuresis in refractory children? Take a look at this study by foreign scholars
Time of Update: 2022-10-13
Fig. 1 Number of days of nocturia in two groups of patients at different time pointsconclusionAs a selective serotonin reuptake inhibitor (SSRI), fluoxetine is a safe and effective treatment regimen for refractory PMNE in children and adolescents with a good initial response.
-
There are 120 million patients with chronic kidney disease in China About 40% of diabetic patients have chronic kidney disease
Time of Update: 2022-09-15
With the progression of the disease, patients with chronic kidney disease have a significantly increased risk of complications and cardiovascular events such as heart failure and premature death.
-
Does diabetes go away on its own
Time of Update: 2022-04-29
Teacher Zhang often pours bitterness to the neighbors: "If you can cure diabetes, you can no longer take injections and medicines every day, you can eat as much as you want, and you don't have to worry about blood sugar rising, that would be great!" It will be realized soon!
-
Antibiotic treatment of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, a list of recommendations from European guidelines
Time of Update: 2022-01-09
CRPA antibiotic selection ➤ For patients with severe infection caused by refractory and drug-resistant CRPA (DTR-CRPA), it is recommended to use ceftaroza/tazobactam ( If effective in vitro) (conditional recommendation, very low quality of evidence) .
-
Functional genes significantly associated with ischemic cardiomyopathy
Time of Update: 2021-12-30
<>. TRS_Editor P{margin-top:0px;margin-bottom:12px;line-height:1. 8;font-family:;font-size:12pt;}. TRS_Editor DIV{margin-top:0px;margin-bottom:12px;line-height:1. 8;font-family:;font-size:12pt;}. TRS_
-
The indications for first-line treatment of Iris vometinib mesylate tablets are planned to be included in the priority review
Time of Update: 2021-12-30
On December 8, the latest announcement on the CDE official website showed that Iris vometinib mesylate tablets are planned to be included in the priority review and are intended for use with epidermal growth factor receptor (EGFR) exon 19 deletion mutations (19DEL) or First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 21 replacement mutation (21L858R) .
-
J Clin Rheumatol: Choroidal thickness can reflect the therapeutic effect of ankylosing spondylitis
Time of Update: 2021-05-20
gov/33779125/" target="_blank" rel="noopener">Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis .
gov/33779125/" target="_blank" rel="noopener">Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis in this message
-
The "definition" of pulmonary hypertension has been rewritten
Time of Update: 2021-04-19
Among them, Professor Wang Qian from the Department of Rheumatology and Immunology, Peking Union Medical College Hospital, gave a wonderful introduction to connective tissue disease pulmonary hypertension (CTD-PAH) and right heart injury, which are summarized as follows.
-
Eur Heart J: Analysis of re-admission of cancer patients treated with percutaneous coronary intervention due to acute myocardial infarction and bleeding within 90 days
Time of Update: 2021-03-20
do?w=%E5%BF%83%E8%A1%80%E7%AE%A1">heart blood vessels magazine field authority Eur Heart published a research article on J, this study was designed to evaluate 90 days of acute myocardial infarction (AMI) and readmission rates in cancer patients undergoing PCI bleeding.
-
Health care commission issued a text, these drugs to fire: oostave, even flowers clear plague, clear the spirit
Time of Update: 2020-10-16
On September 28, the National Health and Health Commission issued a notice on the National Influenza Prevention and Control Work Programme (2020 edition). notice shows that in order to further do a
-
Breakfast is not eaten, dinner is too late to hurt the heart
Time of Update: 2020-09-15
Original title: Breakfast is not eaten, dinner is too late to hurt the heart A new Brazilian study published recently in the European Journal of Preventive Cardiology found that not eating breakfast or dinner for a party directly affects the recovery of heart patients and increases the risk of early death after a heart attack.
-
For the first time in 15 years! Tumor electro-field therapy has been approved for the treatment of glioblastoma
Time of Update: 2020-08-18
On the evening of May 13, Reding Pharmaceuticals announced that China's State Drug Administration had approved the application for the application of the tumor electric field for the treatment of Epden for the treatment of newly diagnosed glioblastoma patients in conjunction with dimoamines, as well as for patients with recurrent glioma as a single therapy.
-
Johnson & Johnson Stelara receives FDA approval for use in children with moderate to severe plaque psoriasis
Time of Update: 2020-08-05
On July 30, Johnson and Johnson's Xi'an Jansen announced that the U.S. FDA had approved its anti-inflammatory drug Stelara (ustekinumab, ustenuma) for moderate to severe plaque psoriasis (PsO) in children (ages 6-11).
